Prosecution Insights
Last updated: November 04, 2026

Silo Pharma Inc.

Technology area: Biotechnology & Pharmaceuticals

4 pending office actions • 3 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready

Analysis

Silo Pharma Inc. is currently managing 4 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 4 distinct examiners and 3 distinct art units, indicating a relatively broad prosecution landscape. This distribution suggests that the company's intellectual property covers several technical sub-fields within the biotechnology sector. Managing such a spread requires a strategy that accounts for the different procedural norms and technical expertise found across the 3 distinct art units. Practitioners must navigate varied examination styles as they address the unique requirements of each assigned unit.

KETCHAM, KAREN A is identified as the busiest examiner, although she is responsible for only 1 pending office action. Because the 4 pending actions are split among 4 different examiners, no single individual dominates the current workload. This lack of concentration requires the legal team to monitor multiple examiner histories and art unit precedents simultaneously. Successfully advancing the portfolio will require a nuanced approach that addresses the specific concerns raised within each of the 3 distinct art units. The diverse nature of the current prosecution suggests a need for broad technical expertise across the pharmaceutical filings.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

4
Total Pending OAs
1
Non-Final OAs
3
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

2
Overdue
0
Due this week
0
Due this month
0
Due in next 60 days
1
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Overdue (2)Due later (1)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

2
Hard (50%)
2
Medium (50%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
Double-patenting + other2 (50%)
Multi-statute (no §101)2 (50%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

4
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

40 h
Manual time on pending OAs
8 h
Time saved (low, 20%)
14 h
Time saved (mid, 35%)
0.3 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
KETCHAM, KAREN A 1 21.1% +39.9%
PEEBLES, KATHERINE 1 35.5% +47.3%
BROWE, DAVID 1 26.8% +27.8%
ROSSI, JULIA ANNE LORRAIN 1 45.7% +61.3%

Hard Cases (3)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.

App #TitleExaminerDue in
18257014 USE OF PSILOCYBIN IN CANCER TREATMENT KETCHAM, KAREN A 59d overdue
18004400 CENTRAL NERVOUS SYSTEM DELIVERY OF PSILOCYBIN ROSSI, JULIA ANNE LORRAIN 84d
18004546 CENTRAL NERVOUS SYSTEM DELIVERY OF NONSTEROIDAL ANTI-INFLAMMATORY DRUGS AND PSILOCYBIN BROWE, DAVID —

Interview Candidates (4)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.

App #TitleExaminerDue in
18004633 CENTRAL NERVOUS SYSTEM DELIVERY OF NONSTEROIDAL ANTI-INFLAMMATORY DRUGS PEEBLES, KATHERINE 60d overdue
18257014 USE OF PSILOCYBIN IN CANCER TREATMENT KETCHAM, KAREN A 59d overdue
18004400 CENTRAL NERVOUS SYSTEM DELIVERY OF PSILOCYBIN ROSSI, JULIA ANNE LORRAIN 84d
18004546 CENTRAL NERVOUS SYSTEM DELIVERY OF NONSTEROIDAL ANTI-INFLAMMATORY DRUGS AND PSILOCYBIN BROWE, DAVID —

Top Art Units

Art UnitApps
1617 2
1614 1
1615 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18257014 USE OF PSILOCYBIN IN CANCER TREATMENT KETCHAM, KAREN A 1614 §103DP Final Rejection 59d overdue Pending Jun 12, 2023
18004633 CENTRAL NERVOUS SYSTEM DELIVERY OF NONSTEROIDAL ANTI-INFLAMMATORY DRUGS PEEBLES, KATHERINE 1617 §103§112DP Non-Final OA 60d overdue Pending Jan 06, 2023
18004546 CENTRAL NERVOUS SYSTEM DELIVERY OF NONSTEROIDAL ANTI-INFLAMMATORY DRUGS AND PSILOCYBIN BROWE, DAVID 1617 §103§112Other Final Rejection — Pending Jan 06, 2023
18004400 CENTRAL NERVOUS SYSTEM DELIVERY OF PSILOCYBIN ROSSI, JULIA ANNE LORRAIN 1615 §103§112 Final Rejection 84d Pending Jan 05, 2023

Managing Silo Pharma Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does Silo Pharma Inc. have?

Silo Pharma Inc. has 4 pending office actions as of November 2026, spread across 3 art units and 4 examiners.

Which USPTO examiner handles the most Silo Pharma Inc. applications?

Karen A Ketcham has the most, with 1 of Silo Pharma Inc.'s pending office actions.

What technology area are Silo Pharma Inc.'s patent applications in?

Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month